Epoxyeicosatrienoic acids and heme oxygenase-1 interaction attenuates diabetes and metabolic syndrome complications. 2012

Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA.

MSCs are considered to be the natural precursors to adipocyte development through the process of adipogenesis. A link has been established between decreased protective effects of EETs or HO-1 and their interaction in metabolic syndrome. Decreases in HO-1 or EET were associated with an increase in adipocyte stem cell differentiation and increased levels of inflammatory cytokines. EET agonist (AKR-I-27-28) inhibited MSC-derived adipocytes and decreased the levels of inflammatory cytokines. We further describe the role of CYP-epoxygenase expression, HO expression, and circulating cytokine levels in an obese mouse, ob/ob(-/-) mouse model. Ex vivo measurements of EET expression within MSCs derived from ob/ob(-/-) showed decreased levels of EETs that were increased by HO induction. This review demonstrates that suppression of HO and EET systems exist in MSCs prior to the development of adipocyte dysfunction. Further, adipocyte dysfunction can be ameliorated by induction of HO-1 and CYP-epoxygenase, i.e. EET.

UI MeSH Term Description Entries
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015126 8,11,14-Eicosatrienoic Acid A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. Homo-gamma Linolenic Acid,8,11,14 Eicosatrienoic Acid,Dihomo-gamma-Linolenic Acid,Dihomogammalinolenic Acid,Ro 12-1989,Dihomo gamma Linolenic Acid,Homo gamma Linolenic Acid,Linolenic Acid, Homo-gamma,Ro 12 1989,Ro 121989
D048909 Diabetes Complications Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE. Complications of Diabetes Mellitus,Diabetes-Related Complications,Diabetic Complications,Diabetes Complication,Diabetes Mellitus Complication,Diabetes Mellitus Complications,Diabetes Related Complications,Diabetes-Related Complication,Diabetic Complication
D051547 Heme Oxygenase-1 A ubiquitous stress-responsive enzyme that catalyzes the oxidative cleavage of HEME to yield IRON; CARBON MONOXIDE; and BILIVERDIN. Hemeoxygenase 1,Heme Oxygenase 1,Oxygenase-1, Heme
D024821 Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. Cardiometabolic Syndrome,Insulin Resistance Syndrome X,Metabolic Syndrome X,Reaven Syndrome X,Dysmetabolic Syndrome X,Metabolic Cardiovascular Syndrome,Metabolic X Syndrome,Syndrome X, Insulin Resistance,Syndrome X, Metabolic,Cardiometabolic Syndromes,Cardiovascular Syndrome, Metabolic,Cardiovascular Syndromes, Metabolic,Metabolic Syndromes,Syndrome X, Dysmetabolic,Syndrome X, Reaven,Syndrome, Cardiometabolic,Syndrome, Metabolic,Syndrome, Metabolic Cardiovascular,Syndrome, Metabolic X,Syndromes, Cardiometabolic,Syndromes, Metabolic,X Syndrome, Metabolic

Related Publications

Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
January 2007, Prostaglandins & other lipid mediators,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
March 2013, Biochemical and biophysical research communications,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
April 2014, Antioxidants & redox signaling,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
December 2004, American journal of physiology. Heart and circulatory physiology,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
June 2007, Neurobiology of disease,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
December 2003, The Journal of biological chemistry,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
November 2014, Chemico-biological interactions,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
August 2007, Biochemical and biophysical research communications,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
January 2014, Current pharmaceutical design,
Angela Burgess, and Luca Vanella, and Lars Bellner, and Michal L Schwartzman, and Nader G Abraham
March 2012, Molecular biology reports,
Copied contents to your clipboard!